sign up log in
Want to go ad-free? Find out how, here.

FPH - Fisher & Paykel Healthcare profile

This is a basic profile of an NZX50 listed company. It is not investment advice. We recommend you contact a qualified adviser if you need more information.

Fisher & Paykel Healthcare

Directory

NZX code: FPH
Short name: Fisher & Paykel Heathcare
Legal name: Fisher & Paykel Healthcare Corporation Limited
Industry sector: Healthcare equpiment
NZX50 rank: 1 of 50
Head office address: 15 Maurice Paykel Place, Auckland, 1061
Chairman: Scott St John
Chief executive: Lewis Gradon 
Financial year ended: March
Locations: New Zealand, Australia
Auditor: Pwc
Bankers: [not revealed]

[back to full list]

Fisher and Paykel Healthcare

Select chart tabs

FHP capitalisation
Source:
FPH rank in NZX50
Source:
FPH share price
Source:
FPH % change to capitalisation
Source:
FPH $mln change to capitalisation
Source:

Financial statement history
 

A. Recent trading and performance summary:

  Total
revenue
NPAT Dividend
per share
fye March bln mln cents
2018 $0.981 $190 21.25
2019 $1.070 $209 23.25
2020 $1.264 $287 27.50
2021 $1.971 $524 38.00
2022 $1.681 $377 39.50
2023 $1.581 $250 40.50

[back to full list]

 

B. Recent financial position summary:

  Total
assets
Total
Liabilities
Equity
ratio
fye March bln mln %
2018 $1.03 $264 74.4
2019 $1.21 $294 75.7
2020 $1.44 $461 68.0
2021 $2.08 $554 73.4
2022 $2.11 $427 79.8
2023 $2.20 $451 79.5

[back to full list]

C. Recent cash flows and positions:

  Cash
inflows
Cash
outflows
Cash and equiv. 
at year end
fye March mln mln mln
2018 $247.8 $277.6 $15.8
2019 $253.3 $238.8 $30.9
2020 $321.4 $314.7 $36.4
2021 $625.3 $575.3 $85.4
2022 $324.3 $325.3 $84.6
2023 $238.2 $208.4 $116.8

[back to full list]

D. Recent key ratio analysis:

  Earnings
per share
Price:Earnings
ratio
NTA/share Dividend
yield
fye March cents annual avg dollars annual avg %
2018 33.4 39.5 1.25 1.52
2019 36.5 43.0 1.49 0.86
2020 50.0 60.8 1.57 0.51
2021 91.1 35.2 2.50 0.98
2022 65.3 37.3 3.06 1.62
2023 43.3 56.9 2.72 2.28

 

[back to full list]

 

Description of trading activities 

Fisher & Paykel Healthcare is a manufacturer, designer and marketer of products and systems for use in respiratory care, acute care, and the treatment of obstructive sleep apnea. Fisher & Paykel Healthcare has a purpose of improving care and outcomes through inspired, world-leading healthcare solutions.

[back to full list]

CEO profile

Lewis Gradon became Managing Director and chief Executive Officer in April 2016. Before that, Gradon spent 15 years as Senior Vice President – Products & Technology, and six years as General Manager – Research and Development. During his 37-year tenure with Fisher & Paykel Healthcare, he has held various engineering positions overseeing the development of arange of product, manufacturing, quality, intellectual property, supply chain, and clinical research functions. 

Chairman profile

Scott St John is Chancellor of the University of Auckland and a director of Mercury Limited, the NEXT Foundation, and Fonterra Cooperative Group Limited. Scott was Chief Executive Officer of First NZ Capital from 2002 to 2017. St John is a Chartered Accountants Australia and New Zealand member and a fellow of the Institute of Finance Professionals of New Zealand. St John has graduated from the University of Auckland with a Bachelor of Commerce, and further rec a Diploma in Business studies.


Links:

Company website: https://www.fphcare.com/nz/
Investor information: https://www.fphcare.com/nz/our-company/investor/
NZX listing: https://www.nzx.com/companies/FPH
Annual reports: https://www.fphcare.com/nz/our-company/investor/

[back to full list]